Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kayode Ogungbenro

Showing results (21-30 of 95) with videos related to

Pageof 10
Sort By:
Cancer Chemotherapy and Pharmacology|March 5, 2016
Predicting survival of pancreatic cancer patients treated with gemcitabine using longitudinal tumour size dataThierry Wendling, Hitesh Mistry, Kayode Ogungbenro, et al.
Journal of Pharmacokinetics and Pharmacodynamics|January 9, 2009
Drug-drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: application to midazolam and a phase I compound. Part 1: comparison of uniresponse and multiresponse designs using PopDesMarylore Chenel, François Bouzom, Leon Aarons, et al.
British Journal of Clinical Pharmacology|November 22, 2025
Translation of a physiologically-based pharmacokinetic model for dabigatran etexilate to the design of a safety and efficacy study in post-partum womenKayode Ogungbenro, Lorna Aucott, Farhad Kamali, et al.
British Journal of Clinical Pharmacology|October 19, 2020
Dose individualisation in oncology using chemotherapy-induced neutropenia: Example of docetaxel in non-small cell lung cancer patientsAurélie Lombard, Hitesh Mistry, Leon Aarons, et al.
Computer Methods and Programs in Biomedicine|September 6, 2005
The use of a modified Fedorov exchange algorithm to optimise sampling times for population pharmacokinetic experimentsKayode Ogungbenro, Gordon Graham, Ivelina Gueorguieva, et al.
Journal of Biopharmaceutical Statistics|March 11, 2008
Incorporating correlation in interindividual variability for the optimal design of multiresponse pharmacokinetic experimentsKayode Ogungbenro, Gordon Graham, Ivelina Gueorguieva, et al.
Clinical Pharmacology and Therapeutics|August 11, 2025
Population Pharmacokinetic Modeling of Glycochenodeoxycholic Acid 3-O-Sulfate (GCDCA-S) as Endogenous Biomarker of OATP1B3 and OAT3 TransportersYuki Ujihira, Viktor Georgiev, Kayode Ogungbenro, et al.
Journal of Pharmacokinetics and Pharmacodynamics|February 8, 2007
Optimal design for multiresponse pharmacokinetic-pharmacodynamic models - dealing with unbalanced designsKayode Ogungbenro, Ivelina Gueorguieva, Oneeb Majid, et al.
The AAPS Journal|October 9, 2020
Simultaneous Ivabradine Parent-Metabolite PBPK/PD Modelling Using a Bayesian Estimation MethodJennifer Lang, Ludwig Vincent, Marylore Chenel, et al.
CPT: Pharmacometrics & Systems Pharmacology|January 29, 2026
Population Physiologically-Based Pharmacokinetic Modeling to Determine Ontogeny: A Quantitative Clinical Pharmacology Example in Pediatric Rare DiseaseYumi Cleary, Bhagwat Prasad, Kayode Ogungbenro, et al.
Pageof 10

Showing results (21-30 of 95) with videos related to

Sort By:
Pageof 10
Cancer Chemotherapy and Pharmacology|March 5, 2016
Predicting survival of pancreatic cancer patients treated with gemcitabine using longitudinal tumour size dataThierry Wendling, Hitesh Mistry, Kayode Ogungbenro, et al.
Journal of Pharmacokinetics and Pharmacodynamics|January 9, 2009
Drug-drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: application to midazolam and a phase I compound. Part 1: comparison of uniresponse and multiresponse designs using PopDesMarylore Chenel, François Bouzom, Leon Aarons, et al.
British Journal of Clinical Pharmacology|November 22, 2025
Translation of a physiologically-based pharmacokinetic model for dabigatran etexilate to the design of a safety and efficacy study in post-partum womenKayode Ogungbenro, Lorna Aucott, Farhad Kamali, et al.
British Journal of Clinical Pharmacology|October 19, 2020
Dose individualisation in oncology using chemotherapy-induced neutropenia: Example of docetaxel in non-small cell lung cancer patientsAurélie Lombard, Hitesh Mistry, Leon Aarons, et al.
Computer Methods and Programs in Biomedicine|September 6, 2005
The use of a modified Fedorov exchange algorithm to optimise sampling times for population pharmacokinetic experimentsKayode Ogungbenro, Gordon Graham, Ivelina Gueorguieva, et al.
Journal of Biopharmaceutical Statistics|March 11, 2008
Incorporating correlation in interindividual variability for the optimal design of multiresponse pharmacokinetic experimentsKayode Ogungbenro, Gordon Graham, Ivelina Gueorguieva, et al.
Clinical Pharmacology and Therapeutics|August 11, 2025
Population Pharmacokinetic Modeling of Glycochenodeoxycholic Acid 3-O-Sulfate (GCDCA-S) as Endogenous Biomarker of OATP1B3 and OAT3 TransportersYuki Ujihira, Viktor Georgiev, Kayode Ogungbenro, et al.
Journal of Pharmacokinetics and Pharmacodynamics|February 8, 2007
Optimal design for multiresponse pharmacokinetic-pharmacodynamic models - dealing with unbalanced designsKayode Ogungbenro, Ivelina Gueorguieva, Oneeb Majid, et al.
The AAPS Journal|October 9, 2020
Simultaneous Ivabradine Parent-Metabolite PBPK/PD Modelling Using a Bayesian Estimation MethodJennifer Lang, Ludwig Vincent, Marylore Chenel, et al.
CPT: Pharmacometrics & Systems Pharmacology|January 29, 2026
Population Physiologically-Based Pharmacokinetic Modeling to Determine Ontogeny: A Quantitative Clinical Pharmacology Example in Pediatric Rare DiseaseYumi Cleary, Bhagwat Prasad, Kayode Ogungbenro, et al.
Pageof 10